Citations

Mayo Clinic

Showing 10 of 108602 citations.

Female and low‐ and middle‐income authorship trends in high‐impact ENT journals (2011–2020)
Jashek‐Ahmed, Farizeh , Daudu, Davina , Heer, Baveena, Ali, Hawa M. , Wiedermann, Joshua P. , Seguya, Amina , (globalohns.org), Members of the Global OHNS Initiative, Ali, Hawa , Wiedermann, Joshua , (globalohns.org), Members of the Global OHNS Initiative

Laryngoscope Investigative Otolaryngology | March 20, 2023 | Volume: 8 | Issue: 2 | Pages: 417-425

10.1002/lio2.1044 | PMID 37090877 Get It

AbstractIntroductionDespite a recent drive to increase diversity, the global academic workforce is skewed in favor of authors from high‐income countries, and women are under‐represented in the published medical literature.ObjectivesTo explore the trends in authorship of three high‐impact otolaryngology journals over a ten‐year period (2011–2020).MethodsJournals selected: JAMA Otolaryngology–Head and Neck Surgery, The Laryngoscope and Rhinology. Articles were reviewed from four issues per journal per year, and data was collected on: time of publication; subspeciality; number of authors; sex of first and last authors; country of practice of first author and country where each study was conducted. Trends were examined though univariate and multivariate logistic regression models.Results2998 articles were included. 93.9% of first authors and 94.2% of studies were from high‐income countries.Women were first authors in 31.5% (n = 912) and senior authors in 18.4% (n = 524) of articles. Female first authorship significantly increased between 2011 and 2020 however female senior authorship remained the same. There have been no significant changes in the proportion of published articles from low‐and middle‐income countries (LMIC) over time (p = .65). Amongst the LMIC articles, 72% came from Brazil, Turkey or China and there were no published papers from countries with a low‐income economy (gross national income per capita of $1085 or less).ConclusionsAlthough female first authorship has increased in the last decade, there has been minimal other demographic change in authorship over this time. High‐impact otolaryngology journals poorly represent academia in low‐and‐middle income countries. There is a need for increased advocacy promoting gender and geographical research equity in academic medicine.Level of EvidenceIII.
Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Sperger, Jamie M. , Helzer, Kyle T. , Stahlfeld, Charlotte N. , Jiang, Dawei , Singh, Anupama , Kaufmann, Katherine R. , Niles, David J. , Héninger, Erika , Rydzewski, Nicholas R. , Wang, Liguo , Wang, Liewei , Yang, Rendong , Ren, Yanan , Kyriakopoulos, Christos E. , Slovin, Susan F. , Soule, Howard R. , Zhao, Shuang G. , Cai, Weibo , Dehm, Scott M. , Lang, Joshua M. , Engle, Jonathan W , Huang, Peng , Kyriakopoulos, Christos E , Slovin, Susan F , Soule, Howard R , Zhao, Shuang G , Kohli, Manish , Tagawa, Scott T , Cai, Weibo , Dehm, Scott M , Lang, Joshua M , Wang, Liguo , Engle, Jonathan W. , Kohli, Manish , Tagawa, Scott T.

Clinical Cancer Research | March 20, 2023 | Volume: 29 | Issue: 12 | Pages: 2324-2335

10.1158/1078-0432.ccr-22-1305 | PMID 36939530 Get It

Abstract Purpose: Men with metastatic castration-resistant prostate cancer (mCRPC) frequently develop resistance to androgen receptor signaling inhibitor (ARSI) treatment; therefore, new therapies are needed. Trophoblastic cell-surface antigen (TROP-2) is a transmembrane protein identified in prostate cancer and overexpressed in multiple malignancies. TROP-2 is a therapeutic target for antibody–drug conjugates (ADC). Experimental Design: TROP-2 gene (TACSTD2) expression and markers of treatment resistance from prostate biopsies were analyzed using data from four previously curated cohorts of mCRPC (n = 634) and the PROMOTE study (dbGaP accession phs001141.v1.p1, n = 88). EPCAM or TROP-2–positive circulating tumor cells (CTC) were captured from peripheral blood for comparison of protein (n = 15) and gene expression signatures of treatment resistance (n = 40). We assessed the efficacy of TROP-2–targeting agents in a mouse xenograft model generated from prostate cancer cell lines. Results: We demonstrated that TACSTD2 is expressed in mCRPC from luminal and basal tumors but at lower levels in patients with neuroendocrine prostate cancer. Patients previously treated with ARSI showed no significant difference in TACSTD2 expression, whereas patients with detectable AR-V7 expression showed increased expression. We observed that TROP-2 can serve as a cell surface target for isolating CTCs, which may serve as a predictive biomarker for ADCs. We also demonstrated that prostate cancer cell line xenografts can be targeted specifically by labeled anti–TROP-2 agents in vivo. Conclusions: These results support further studies on TROP-2 as a therapeutic and diagnostic target for mCRPC.
Mass spectrometry‐based proteomic profiling of sonicate fluid differentiates Staphylococcus aureus periprosthetic joint infection from non‐infectious failure: A pilot study
Fisher, Cody R. , Mangalaparthi, Kiran K. , Greenwood‐Quaintance, Kerryl E. , Abdel, Matthew P. , Pandey, Akhilesh , Patel, Robin , Patel, Robin , Pandey, Akhilesh , Abdel, Matthew P , Fisher, Cody , Greenwood-Quaintance, Kerryl

PROTEOMICS – Clinical Applications | March 20, 2023 | Volume: 17 | Issue: 5 | Pages: No page available

10.1002/prca.202200071 | PMID 36938941 Get It

AbstractPurposeThis pilot study aimed to use proteomic profiling of sonicate fluid samples to compare host response during Staphylococcus aureus‐associated periprosthetic joint infection (PJI) and non‐infected arthroplasty failure (NIAF) and identify potential novel biomarkers differentiating the two.Experimental designIn this pilot study, eight sonicate fluid samples (four from NIAF and four from S. aureus PJI) were studied. Samples were reduced, alkylated, and trypsinized overnight, followed by analysis using liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) on a high‐resolution Orbitrap Eclipse mass spectrometer. MaxQuant software suite was used for protein identification, filtering, and label‐free quantitation.ResultsPrincipal component analysis of the identified proteins clearly separated S. aureus PJI and NIAF samples. Overall, 810 proteins were identified based on their detection in at least three out of four samples from each group; 35 statistically significant differentially abundant proteins (DAPs) were found (two‐sample t‐test p‐values ≤0.05 and log2fold‐change values ≥2 or ≤−2). Gene ontology pathway analysis found that microbial defense responses, specifically those related to neutrophil activation, to be increased in S. aureus PJI compared to NIAF samples.Conclusion and clinical relevanceProteomic profiling of sonicate fluid using LC‐MS/MS differentiated S. aureus PJI and NIAF in this pilot study. Further work is needed using a larger sample size and including non‐S. aureus PJI and a diversty of NIAF‐types.
Focal epilepsies: Update on diagnosis and classification
Nascimento, Fábio A. , Peters, Jurriaan M. , Bensalem‐Owen, Meriem, Rampp, Stefan , Wirrell, Elaine , Blümcke, Ingmar , Tatum, William O. , Rampp, Stefan , Wirrell, Elaine C , Blümcke, Ingmar , Tatum, William O , Beniczky, Sándor , Nascimento, Fábio A , Friedman, Daniel , Cendes, Fernando

Epileptic Disorders | March 20, 2023 | Volume: 25 | Issue: 1 | Pages: 1-17

10.1002/epd2.20045 | PMID 36938903 Get It

AbstractCorrectly diagnosing and classifying seizures and epilepsies is paramount to ensure the delivery of optimal care to patients with epilepsy. Focal seizures, defined as those that originate within networks limited to one hemisphere, are primarily subdivided into focal aware, focal impaired awareness, and focal to bilateral tonic–clonic seizures. Focal epilepsies account for most epilepsy cases both in children and adults. In children, focal epilepsies are typically subdivided in three groups: self‐limited focal epilepsy syndromes (e.g., self‐limited epilepsy with centrotemporal spikes), focal epilepsy of unknown cause but which do not meet criteria for a self‐limited focal epilepsy syndrome, and focal epilepsy of known cause (e.g., structural lesions—developmental or acquired). In adults, focal epilepsies are often acquired and may be caused by a structural lesion such as stroke, infection and traumatic brain injury, or brain tumors, vascular malformations, metabolic disorders, autoimmune, and/or genetic causes. In addition to seizure semiology, neuroimaging, neurophysiology, and neuropathology constitute the cornerstones of a diagnostic evaluation. Patients with focal epilepsy who become drug‐resistant should promptly undergo assessment in an epilepsy center. After excluding pseudo‐resistance, these patients should be considered for presurgical evaluation as a means to identify the location and extent of the epileptogenic zone and assess their candidacy for a surgical procedure. The goal of this seminar in epileptology is to summarize clinically relevant information concerning focal epilepsies. This contributes to the ILAE's mission to ensure that worldwide healthcare professionals, patients, and caregivers continue to have access to high‐quality educational resources concerning epilepsy.
Is thalamic deep brain stimulation synergistic with vagus nerve stimulation in drug‐resistant genetic generalized epilepsy?
Khan, Aafreen , Middlebrooks, Erik H. , Freund, Brin , Grewal, Sanjeet S. , Tatum, William O. , Grewal, Sanjeet , Middlebrooks, Erik H

Epileptic Disorders | March 20, 2023 | Volume: 25 | Issue: 3 | Pages: 406-409

10.1002/epd2.20038 | PMID 36938890 Get It

AbstractNeuromodulation in epilepsy is a proven treatment for people with drug‐resistant focal epilepsy. Dual device therapies are increasingly utilized in people with drug‐resistant epilepsy. Vagus nerve stimulation (VNS) and deep brain stimulation (DBS) target the thalamus involving the primary neurobiological network in patients with genetic generalized epilepsy (GGE). We report a novel case of combined neuromodulation in a patient with drug‐resistant GGE who achieved a partial response with seizure reduction after VNS implantation yet following VNS‐DBS polyneurostimulation gradually achieved prolonged seizure freedom. We speculate that by combining the indirect activating effects of VNS with the direct inhibitory effects of DBS, this may provide synergy to thalamic modulated networks. We hypothesize a “rational polytherapy” may exist in some patients with GGE undergoing dual neuromodulation.
Clonal hematopoiesis of indeterminate potential and clonal cytopenias of undetermined significance: 2023 update on clinical associations and management recommendations
Mangaonkar, Abhishek A. , Patnaik, Mrinal M.

American Journal of Hematology | March 20, 2023 | Volume: 98 | Issue: 6 | Pages: 951-964

10.1002/ajh.26915 | PMID 36938794 Get It

AbstractCondition OverviewClonal hematopoiesis (CH) refers to age‐associated expansion of somatic variants in hematopoietic stem and progenitor cells (HSPC).DiagnosisCH of indeterminate potential (CHIP) is operationally defined as pathogenic variants in HSPCs at a variant allele frequency ≥2%.Clinical AssociationsCH is associated with increased occurrence of several hematological conditions such as cytopenias (also called clonal cytopenia of undetermined significance), hematological (predominantly myeloid but also lymphoid) neoplasms, cytosis (including monocytosis), and non‐hematological conditions such as atherosclerotic cardiovascular and cerebrovascular disease, ischemic congestive heart failure, venous thromboembolism, type 2 diabetes mellitus, chronic obstructive pulmonary disease, osteoporosis, gout, with a potential protective effect in Alzheimer's disease (AD).Management RecommendationsAs of now, there is limited prospective data for CH testing; however, CH detection is becoming increasingly prevalent due to ubiquitous use of somatic and germline NGS testing. This in addition to data suggesting that therapy related myeloid neoplasm (tMN) in many cases is preceded by the detection of CH clones, has led to the establishment of CH clinics at several institutions. At our institution, on a research basis, we currently recommend testing for CH for individuals with persistent (≥4 months) unexplained cytopenias, in patients with malignancies prior to adjuvant cytotoxic chemotherapy and/or radiation or radionuclide therapy, screening prior to autologous hematopoietic stem cell transplantation and chimeric antigen receptor T cell (CAR‐T) therapy and to assess as to whether or not, potential germline mosaic variants actually represent CH.
Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy
Shah, Vishal , McNatty, Andrea , Simpson, Lacey , Ofori, Henry , Raheem, Farah , Shah, Vishal

Biomedicines | March 20, 2023 | Volume: 11 | Issue: 3 | Pages: 950

10.3390/biomedicines11030950 | PMID 36979929 Get It

Objective: This study is a comprehensive review of the clinical pharmacology, pharmacokinetics, efficacy, safety, and clinical applicability of amivantamab-vmjw for metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (exon20ins) mutation. Data Synthesis: The literature search to identify clinical trials returned only the CHRYSALIS phase 1 study. In a phase I trial, amivantamab-vmjw was associated with an overall response rate (ORR) of 40% (95% CI, 29–51) in the EGFR exon20ins NSCLC patient population (n = 81) after platinum-based chemotherapy. There were 3 complete responses (CRs) and 29 partial responses (PRs). The median duration of response (DOR) was 11.1 months (95% CI, 6.9—not reached; NR). The median progression-free survival (PFS) was 8.3 months (95% CI, 6.5–10.9), and overall survival (OS) was 22.8 months (95% CI, 14.6—NR). Application to Clinical Practice: This review summarizes the pharmacology, clinical evidence, and use of amivantamab-vmjw for patients with locally advanced or metastatic NSCLC with EGFR exon20ins mutation. Conclusion: The FDA approval of amivantamab-vmjw, the first bispecific antibody to target the exon20ins mutation, represents an important advancement in the treatment of patients with NSCLC with limited effective treatment options. The initial findings of the CHRYSALIS trial demonstrate an overall tumor response benefit with an acceptable safety profile.
Emerging targets for therapy in ALD: Lessons from NASH
Singal, Ashwani K. , Shah, Vijay H. , Malhi, Harmeet , Malhi, Harmeet , Singal, Ashwani K

Hepatology | March 20, 2023 | Volume: 80 | Issue: 1 | Pages: 223-237

10.1097/hep.0000000000000381 | PMID 36938877 Get It

Alcohol-associated liver disease due to harmful alcohol use and NAFLD associated with metabolic syndrome are the 2 most common liver diseases worldwide. Control of respective risk factors is the cornerstone in the long-term management of these diseases. Furthermore, there are no effective therapies. Both diseases are characterized by metabolic derangements; thus, the focus of this review was to broaden our understanding of metabolic targets investigated in NAFLD, and how these can be applied to alcohol-associated liver disease. Conserved pathogenic pathways such as dysregulated lipid metabolism, cell death pathways including apoptosis and activation of innate immune cells, and stellate cells mediate both alcohol and NAFLDs, resulting in histological abnormalities of steatosis, inflammation, fibrosis, and cirrhosis. However, pathways such as gut microbiome changes, glucose metabolism and insulin resistance, inflammatory signaling, and microRNA abnormalities are distinct in these 2 diseases. In this review article, we describe conserved and distinct pathogenic pathways highlighting therapeutic targets that may be of potential in both diseases and those that are unique to each disease.
Advances in reconstructive urology: A review of the 2022 literature
Bearrick, Elizabeth , Simhan, Jay , Sterling, Joshua , Nikolavsky, Dmitriy

International Journal of Reconstructive Urology | March 20, 2023 | Volume: 1 | Issue: 1 | Pages: 4-11

10.4103/ijru.ijru_3_23 Get It

ABSTRACT Reconstructive urology encompasses a broad spectrum of lower and upper urinary tract diseases. A recent society of genitourinary reconstructive mission statement emphasized the desire to promote and support research in the growing fields of tissue engineering, device design, patient-reported outcomes, and validated measurement tools for urethral stricture disease. The purpose of this article was to identify and highlight the high-impact recent literature published within reconstructive urology during the past year. Original research, systematic reviews, and videos from the Gold Journal, BJUI, World Journal of Urology International, SIU Journal, Neurourology Urodynamics, Journal of Urology, and European Urology were included.
Mitochondrial Base Editing: Recent Advances towards Therapeutic Opportunities
Kar, Bibekananda , Restrepo-Castillo, Santiago , Sabharwal, Ankit , Ekker, Stephen C. , Castillo, Santiago R , Ekker, Stephen C , Sabharwal, Ankit , Kar, Bibekananda , Clark, Karl J.

International Journal of Molecular Sciences | March 20, 2023 | Volume: 24 | Issue: 6 | Pages: 5798

10.3390/ijms24065798 | PMID 36982871 Get It

Mitochondria are critical organelles that form networks within our cells, generate energy dynamically, contribute to diverse cell and organ function, and produce a variety of critical signaling molecules, such as cortisol. This intracellular microbiome can differ between cells, tissues, and organs. Mitochondria can change with disease, age, and in response to the environment. Single nucleotide variants in the circular genomes of human mitochondrial DNA are associated with many different life-threatening diseases. Mitochondrial DNA base editing tools have established novel disease models and represent a new possibility toward personalized gene therapies for the treatment of mtDNA-based disorders.